10-Q: HCW Biologics Faces Liquidity Crisis, Nasdaq Delisting Threat

HCW Biologics reported a reduced net loss for Q3 2025 but faces substantial doubt about its going concern ability, a Nasdaq compliance deadline, and ongoing legal and construction challenges.

Summary

• HCW Biologics reported a net loss of $8.7 million for the nine months ended September 30, 2025, a significant improvement from $26.7 million in the prior year, largely due to a $2.0 million insurance reimbursement for legal fees and the absence of a $1.3 million nonoperating loss from a criminal scheme.
• Revenues plummeted to $27,222 for the nine months ended September 30, 2025, down from $2.2 million in the same period last year, primarily due to the one-year suspension of the Wugen License.
• The company has substantial doubt about its ability to continue as a going concern, with cash and cash equivalents at $1.1 million as of September 30, 2025.
• HCW Biologics is non-compliant with Nasdaq's Equity Rule (minimum $2.5 million stockholders' equity) and has been granted an extension until December 31, 2025, to regain compliance for this rule, and until February 16, 2026, for all other listing rules.
• A $7.7 million debt was extinguished through restructuring or conversion to equity in the nine months ended September 30, 2025, involving officers, directors, and significant stockholders.
• The company faces a demand from Cogent Bank to cure mechanics liens on its manufacturing facility loan within 30 days (as of October 24, 2025), indicating a loan default, with negotiations for a forbearance agreement ongoing.
• A Phase 1 clinical trial (NCT07049328) for HCW9302 in alopecia areata is expected to dose its first patient in Q4 2025, with two clinical sites actively screening patients.
• Negotiations are ongoing to finalize an amendment to the exclusive worldwide license agreement with WY Biotech for HCW11-006, with the $7.0 million upfront license fee payment extended and further revisions proposed.

Sentiment

Score: 3

Explanation: The company faces severe liquidity issues, substantial doubt about its going concern ability, and Nasdaq non-compliance. While there's progress in clinical development and debt restructuring, these are overshadowed by critical financial challenges, including a significant revenue drop, a loan default demand, and substantial unpaid legal fees. The overall financial health is precarious.

Positives

• Net loss significantly decreased to $8.7 million for the nine months ended September 30, 2025, from $26.7 million in the prior year, primarily due to a $2.0 million insurance reimbursement for legal fees and the absence of a $1.3 million nonoperating loss.
• A confidential Settlement Agreement with ImmunityBio was reached on July 13, 2024, resolving a significant arbitration and related complaint without requiring any monetary payments from the company.
• Successfully extinguished $7.7 million of debt through restructuring and conversion to equity in the nine months ended September 30, 2025, strengthening the balance sheet.
• Raised $7.0 million in gross proceeds through equity issuances in the nine months ended September 30, 2025, including $2.2 million net proceeds from the Standby Equity Purchase Agreement (SEPA).
• Received an extension from Nasdaq until December 31, 2025, to regain compliance with the Equity Rule and until February 16, 2026, for all other listing rules.
• Progress in clinical development pipeline, with a Phase 1 trial for HCW9302 in alopecia areata expected to dose its first patient in Q4 2025, and two sites actively screening.
• Presented positive preclinical data for second-generation multi-specific T-cell engagers and pembrolizumab-based immunotherapeutics at the Society for Immunotherapy of Cancer (SITC) annual meeting in November 2025.
• HCW9206 shows potential as a superior reagent for CAR-T manufacturing, with a GMP master cell bank established and a drug master file filed with the FDA, and the company is seeking a commercial partner.

Negatives

• Substantial doubt exists about the ability to continue as a going concern for at least 12 months from the financial statements' issuance date, with management concluding no mitigating circumstances alleviated this doubt.
• Cash and cash equivalents decreased significantly to $1.1 million as of September 30, 2025, from $4.7 million at December 31, 2024.
• Revenues for the nine months ended September 30, 2025, plummeted to $27,222 from $2.2 million in the prior year, primarily due to the suspension of the Wugen License.
• Non-compliant with Nasdaq Listing Rule 5550(b)(1) (Equity Rule) as of June 30, 2025, requiring a minimum $2.5 million in stockholders' equity.
• Cogent Bank issued a demand letter on October 24, 2025, requiring the company to cure mechanics liens on its manufacturing facility loan within 30 days, indicating a loan default.
• The company has $12.1 million in legal fees incurred but not yet paid, included in Accounts payable, and is negotiating payment plans with law firms.
• Negotiations for the WY Biotech License amendment are ongoing, with the $7.0 million upfront license fee payment extended and further revisions proposed, delaying potential revenue recognition.
• The Wugen License was suspended for one year until May 29, 2026, halting Wugen's clinical trial due diligence obligations and annual reimbursement for R&D expenses.
• Property, plant and equipment, net, decreased to $22.5 million at September 30, 2025, from $22.9 million at December 31, 2024, reflecting ongoing construction issues and depreciation.

Risks

• Substantial doubt about the ability to continue as a going concern due to sustained operating losses, negative operating cash flows, and negative working capital position.
• Risk of delisting from Nasdaq if compliance with the Equity Rule (minimum $2.5 million stockholders' equity) is not achieved by December 31, 2025, and all other listing rules by February 16, 2026.
• Inability to raise additional capital through equity sales, business development transactions, or debt arrangements, which could lead to curtailment or cessation of operations.
• Potential for foreclosure or other legal actions related to the $6.2 million Cogent Bank loan due to mechanics liens and the bank's demand for cure.
• Uncertainty and potential failure of ongoing negotiations for the WY Biotech License amendment, which could impact future licensing revenue.
• Impact of the Wugen License suspension, including loss of revenue and potential termination of the license if alternate licensees are found.
• Exposure to macroeconomic headwinds, including inflationary pressures, high interest rates, global supply chain disruptions, geopolitical tensions, and U.S. government shutdowns, which can affect costs, timing of clinical trials, and access to capital markets.
• Risks associated with clinical development, including delays, failures, and increased costs for product candidates, as well as the inability to obtain regulatory approval.
• Dependence on intellectual property rights and the risk of future disputes, despite the recent settlement with ImmunityBio.
• Significant outstanding legal fees of $12.1 million, which could strain liquidity if payment plans are not successfully negotiated.
• Market risk related to the limited marketability and fair value fluctuations of the investment in Wugen common stock.

Future Outlook

The company plans to advance its clinical development programs, including dosing the first patient in a Phase 1 trial for HCW9302 in Q4 2025, and expand its discovery, research, and preclinical activities. It intends to pursue business development transactions, such as out-licensing TRBC-based molecules and seeking a commercial partner for HCW9206. The company expects research and development expenses to increase as clinical activities ramp up. Management acknowledges substantial doubt about its ability to continue as a going concern and states that if additional capital is not raised, it will revise its business plan and reduce costs, potentially leading to curtailment or cessation of operations.

Management Comments

• "We believe our lead product candidates represent a novel immunotherapeutic approach and a clinically promising new class of senotherapeutic drugs for the treatment of age-related diseases."
• "Our focus continues to be to develop protein-based immunotherapies that are administered by subcutaneous injection."
• "We remain focused on diseases promoted by chronic inflammation driven by senescence, including cancer, especially age-related diseases. The diseases we will target will have no curative FDA approved treatments."
• "We have selected programs that include life-threatening diseases, such as pancreatic and ovarian cancer, as well as quality-of-life indications, such as alopecia areata and senile lentigo."
• "If the Company is not successful in raising additional capital through these activities, management intends to revise its business plan and reduce costs. If such revisions are insufficient, the Company may have to curtail or cease operations."
• "Management concluded that there were no mitigating circumstances which alleviated the substantial doubt over its ability to continue as a going concern."

Industry Context

The biopharmaceutical industry is currently navigating significant headwinds, including inflationary pressures, high interest rates, ongoing global supply chain disruptions, and geopolitical tensions. There's a growing trend to re-shore pharmaceutical manufacturing, which HCW Biologics aims to address with its facility. The company's focus on immunotherapies for age-related diseases and cancer aligns with major research areas. Its efforts to improve CAR-T therapies and develop second-generation immune checkpoint inhibitors position it within highly competitive and innovative segments of oncology and autoimmune treatment, seeking to overcome limitations of existing therapies.

Comparison to Industry Standards

• The company's founder and CEO, Dr. Hing C. Wong, has a strong track record, having discovered and developed Anktiva (ALT-803), an IL-15 agonist receptor, which was acquired by ImmunityBio for $1.0 billion in 2017 and received FDA approval for bladder cancer in 2024.
• Preclinical and non-human primate studies for HCW9302 demonstrated an approximately 1,000-fold higher affinity for the IL2R than IL-2 and a longer serum half-life, potentially offering therapeutic advantages over recombinant IL-2 by being well tolerated.
• The company's second-generation T-cell engagers, developed using the TRBC platform, aim to improve upon existing FDA-approved T-cell engagers by simultaneously targeting cancer antigens and CD3 activation while reducing immunosuppression in the tumor microenvironment, a key challenge in solid tumors.
• HCW11-040, a novel pembrolizumab-based immunotherapeutic, demonstrated potent anti-pancreatic cancer activities and outperformed pembrolizumab as monotherapy in preclinical models by neutralizing TGFand activating effector immune cells, suggesting an advancement over first-generation immune checkpoint inhibitors like Keytruda.
• Studies suggest HCW9206 could be a superior reagent for CAR-T viral transduction compared to the standard anti-CD3/anti-CD28/IL-2 method, potentially reducing costs and improving clinical efficacy by generating a large population of CAR-Ts with a stem cell-like memory T cell (Tscm) phenotype, which enhances persistence and targeted killing.

Management Changes

Corporate Governance

Legal Proceedings

• Settlement Agreement with ImmunityBio (Altor BioScience, NantCell) was entered on July 13, 2024, resolving a previously disclosed arbitration and a related complaint. The agreement included mutual general releases, no monetary payments, and dismissal of proceedings with prejudice on December 24, 2024. Intellectual property was transferred to ImmunityBio, but HCWB retained rights to HCW9302, HCW9206, HCW9201, and the TOBI platform for non-oncology indications.
• BE&K Complaint: On April 17, 2025, BE&K Building Group filed a complaint in Florida Circuit Court related to unpaid invoices for the construction of the company's manufacturing facilities. Subcontractors filed counterclaims and cross-claims. A motion for summary judgment was filed by B&I Contractors, Inc. on August 8, 2025. The case is set for a five-day jury trial in December 2026.
• Fisk Electric Company Complaint: On April 28, 2025, Fisk Electric Company filed a complaint against the company, BE&K, and other defendants in Florida Circuit Court, also related to the construction litigation.
• Cogent Bank Demand Letter: On October 24, 2025, Cogent Bank notified the company that it exercised its discretion to demand the cure of mechanics liens within thirty days, citing a default provision in the 2022 Loan Agreement. Negotiations for a forbearance agreement are ongoing.

Related Party Transactions

• Conversion of $7.7 million of debt, including Senior Secured Notes and unsecured promissory notes, into equity involved officers, directors, and other significant stockholders. This included Dr. Hing C. Wong ($2.4 million), Rebecca Byam ($220,000), Lee Flowers ($25,000), Scott T. Garrett ($140,000), Gary M. Winer ($60,000), and Rick S. Greene ($25,000).
• Dr. Hing C. Wong, Founder and CEO, provided a personal guaranty and pledge for a $150,000 promissory note issued on May 8, 2025.
• An insurance reimbursement of $2.0 million for legal fees incurred on behalf of Dr. Hing C. Wong in connection with his defense in the ImmunityBio arbitration was received during the nine months ended September 30, 2025.
• In the May 2025 financing, the difference of $10.2 million between the gross proceeds and the fair value of securities issued (including repriced warrants from November 2024) was deemed an equity dividend to an existing institutional investor.

Stakeholder Impact

• Shareholders face significant risks including potential delisting from Nasdaq, substantial dilution from ongoing equity raises (SEPA), and high uncertainty regarding the company's ability to continue as a going concern, which could lead to significant share price volatility.
• Employees may be impacted by potential cost reductions and revised business plans if the company fails to raise additional capital, which could affect job security and compensation.
• Customers and licensees, particularly Wugen Inc., have suspended their license agreement, impacting future revenue streams. Negotiations with WY Biotech for a license amendment are ongoing, creating uncertainty for that potential partnership.
• Creditors, including Cogent Bank, have initiated actions due to loan defaults and mechanics liens, potentially leading to foreclosure on the manufacturing facility. Law firms are owed $12.1 million in outstanding legal fees.
• Suppliers and contractors involved in the manufacturing facility construction have filed mechanics liens due to unpaid invoices, indicating strained relationships and potential future difficulties in securing services.

Next Steps

• Dose the first patient in the Phase 1 clinical trial (NCT07049328) for HCW9302 in alopecia areata in Q4 2025.
• Finalize the amendment terms for the exclusive worldwide license agreement with WY Biotech for HCW11-006.
• Seek alternate licensees for the molecules previously licensed to Wugen Inc. (ex vivo use) following the license suspension.
• Identify a strong commercial partner for HCW9206 as a reagent for CAR-T based manufacturing processes.
• Negotiate a forbearance agreement with Cogent Bank to provide additional time to comply with the demand to cure mechanics liens.
• Regain compliance with Nasdaq's Equity Rule by December 31, 2025, and all other continued listing rules by February 16, 2026.
• Establish a reasonable payment plan with law firms for the $12.1 million in outstanding legal fees.
• Continue pursuing financing alternatives to provide funding needed to complete the construction and renovation of the biologics manufacturing facility.
• Continue clinical development of TRBC-based molecules, including T-cell engagers and second-generation immune checkpoint inhibitors.
• Enter into a supply agreement with ImmunityBio for HCW9218 molecules.

Key Dates

Recommendation

HCW Biologics is in a highly precarious financial position, facing substantial doubt about its ability to continue as a going concern, a critically low cash balance of $1.1 million, and non-compliance with Nasdaq listing rules. The significant drop in revenue, a demand for loan default cure from Cogent Bank, and $12.1 million in unpaid legal fees underscore severe liquidity and operational challenges. While clinical pipeline progress and debt restructuring offer some positive developments, they are insufficient to offset the immediate and existential financial risks. The high probability of further dilution, potential delisting, and the risk of curtailing operations make the stock a strong sell for investors.

Keywords

Biopharmaceutical, Immunotherapy, Oncology, Autoimmune Disease, Inflammaging, CAR-T, Nasdaq Compliance, Going Concern, Clinical Trials, SEC Filing, 10-Q, Debt Restructuring, Equity Financing, Biologics Manufacturing, Legal Proceedings